Chemical Component Summary

NameTAXOL
Identifiersn/a
FormulaC47 H51 N O14
Molecular Weight853.906
TypeNON-POLYMER
Isomeric SMILESCC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](c5ccccc5)NC(=O)c6ccccc6)O)O)OC(=O)c7ccccc7)(CO4)OC(=O)C)O)C)OC(=O)C
InChIInChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1
InChIKeyRCINICONZNJXQF-MZXODVADSA-N

Chemical Details

Formal Charge0
Atom Count113
Chiral Atom Count11
Bond Count119
Aromatic Bond Count18

Drug Info: DrugBank

DrugBank IDDB01229 
NamePaclitaxel
Groups
  • vet_approved
  • approved
DescriptionPaclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
Synonyms
  • Nanoparticulate paclitaxel
  • 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
  • BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,
  • liposomal encapsulated paclitaxel
  • ABI-007 COMPONENT PACLITAXEL
Brand Names
  • Paclitaxel Protein Bound Particles Albumin Bound
  • Paclitaxel Injection, USP
  • Paclitaxel Injection
  • Onxol
  • Paclitaxel Injection USP
IndicationUsed in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
Categories
  • Agents Causing Muscle Toxicity
  • Albumins
  • Amino Acids, Peptides, and Proteins
  • Antimitotic Agents
  • Antineoplastic Agents
ATC-Code
  • L01CD01
  • L01CD51
CAS number33069-62-4

Drug Targets

NameTarget SequencePharmacological ActionActions
Tubulin beta-1 chainMREIVHIQIGQCGNQIGAKFWEMIGEEHGIDLAGSDRGASALQLERISVY...unknowninhibitor
Apoptosis regulator Bcl-2MAHAGRTGYDNREIVMKYIHYKLSQRGYEWDAGDVGAAPPGAAPAPGIFS...unknowninhibitor
Microtubule-associated protein 4MADLSLADALTEPSPDIEGEIKRDFIATLEAEAFDDVVGETVGKTDYIPL...unknown
Microtubule-associated protein 2MADERKDEAKAPHWTSAPLTEASAHSHPPEIKDQGGAGEGLVRSANGFPY...unknown
Microtubule-associated protein tauMAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQT...unknown
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL428647
PubChem 36314
ChEMBL CHEMBL428647
ChEBI CHEBI:45863